Duloxetine for fibromyalgia - horizon scanning review
NHSC
Record ID 32005001216
English
Authors' objectives:
This study aims to summarise the currently available evidence on Duloxetine for fibromyalgia
Authors' recommendations:
Duloxetine (Yentreve, Cymbalta, LY 248686) is a dual serotonin and noradrenaline re-uptake inhibitor (SNRI) in phase III trials for the management of the symptoms of fibromyalgia. If successful in licensing it will be the first pharmaceutical licensed for fibromyalgia. Two 12 week randomised, placebo controlled trials in 207 patients and 354 women, found that duloxetine improved the Fibromyalgia Impact Questionnaire (FIQ) score, and Brief Pain Inventory 24-hour average pain score respectively. A phase III trial of duloxetine over 12 months is planned to start in October 2005 and will evaluate pain severity and patient-reported improvement in 320 women with fibromyalgia.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Selective Serotonin Reuptake Inhibitors
- Antidepressive Agents
- Fibromyalgia
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.